Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemiaJohn Hornberger
Cedar Associates LLC, Menlo Park, CA 94025, USA
Leuk Lymphoma 53:225-34. 2012
..Results were most sensitive to time horizon, discount rate and unit drug cost for rituximab. Within the limitations of modeling long-term outcomes, R-FC is cost-effective for previously untreated CLL...
- US insurance program's experience with a multigene assay for early-stage breast cancer
John Hornberger
Am J Manag Care 17:e194-202. 2011
..This study was performed to assess the economic implication of the assay in community practices from the perspective of a US payer...
- Cost consequences of HIV-associated lipoatrophy
J Hornberger
Cedar Associates LLC, Menlo Park, CA, USA
AIDS Care 21:664-71. 2009
..This could have implications for deciding whether to undergo a restorative procedure, which procedure to undergo, and whether to pursue other options that may include switching ARV regimens...
- Rechargeable spinal cord stimulation versus non-rechargeable system for patients with failed back surgery syndrome: a cost-consequences analysis
John Hornberger
Cedar Associates LLC, Menlo Park, CA 94025, USA
Clin J Pain 24:244-52. 2008
..The study objective is to estimate the average difference in lifetime costs between rechargeable and non-rechargeable pulse generators used in treatment with SCS for failed back surgery syndrome...
- Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
John Hornberger
Cedar Associates LLC, Menlo Park, CA, USA
Leuk Lymphoma 49:227-36. 2008
..The cost-effectiveness ratio of R-CVP compared with CVP is projected to be cost-effective in the United States under a range of sensitivity analyses...
- A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy
John Hornberger
The SPHERE Institute Acumen, LLC, Burlingame, California, USA
Med Decis Making 27:789-821. 2007
..To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS)...
- Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
John Hornberger
The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
J Clin Virol 36:283-91. 2006
..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
- The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase
J Hornberger
Acumen LLC The SPHERE Institute, Burlingame, CA 94010, USA
J Viral Hepat 13:377-86. 2006
..Thus treatment of PNALT with peginterferon alpha-2a (40 kDa) plus ribavirin is projected to reduce the incidence of cirrhosis, increase life expectancy and have an acceptable cost-effectiveness ratio from a societal perspective...
- Risks and costs of end-stage renal disease after heart transplantation
J Hornberger
Roche Global Pharmacoeconomic Research, Roche Pharmaceuticals, Palo Alto, California, USA
Transplantation 66:1763-70. 1998
..To estimate the risks and costs of end-stage renal disease (ESRD) after heart transplantation...
- Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
John Hornberger
The SPHERE Institute Acumen, Burlingame, California 94010, USA
AIDS Res Hum Retroviruses 22:240-7. 2006
..5 years among treatment-experienced HIV-infected patients. The cost-effectiveness of ENF is comparable to many existing treatment and prevention management strategies for HIV...
- Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
John Hornberger
SPHERE Institute and Acumen LLC, Burlingame, California 94010, USA
Ann Intern Med 145:317-25. 2006
..12 to 5.42 cases per 1000 person-years. Median follow-up was 3.1 years, and relative risk reduction was 51.3% (95% CI, 44.2% to 57.6%)...
- Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy
John Hornberger
The SPHERE Institute Acumen, LLC, 1415 Rollins Road, Suite 110, Burlingame, CA 94010, USA
HIV Clin Trials 6:92-102. 2005
..Enfuvirtide (ENF) plus an optimized background (OB) antiretroviral regimen delays virological failure (VF), reduces HIV-1 viral load, and increases CD4 count compared with OB only in pretreated patients...
- The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
John Hornberger
Cedar Associates LLC, Menlo Park, CA, USA
Eur J Haematol 85:484-91. 2010
..To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden...
- Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
John Hornberger
The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
Am J Manag Care 11:313-24. 2005
....
- Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma
Jennie H Best
Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
Value Health 8:462-70. 2005
..CONCLUSION: R-CHOP significantly increases mean OS up to 4 years compared with CHOP, and its cost-effectiveness ratio compares favorably with other oncology treatments in widespread use...
- Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies
Gary H Lyman
Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
Cancer 109:1011-8. 2007
..The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14...
- Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004)
Mark Holodniy
AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94340, USA
J Acquir Immune Defic Syndr 44:20-9. 2007
..To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection...
- Capecitabine plus docetaxel combination therapy
Shailendra Verma
Department of Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Canada
Cancer 103:2455-65. 2005
..The current study evaluated the cost-effectiveness of the capecitabine/docetaxel combination versus docetaxel monotherapy, comparing the gain in quality-adjusted survival with associated health care costs...
- Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
Milton C Weinstein
Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Value Health 6:9-17. 2003
..This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies...
- Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
Anatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
Am J Kidney Dis 40:439-46. 2002
..Recommendations of current US and European guidelines, which encourage the use of SC administration, not only have a sound rationale in terms of efficacy and safety, but also have a sound economic basis...
